Academic Journal
Q1Journal of Psychopharmacology
About Journal of Psychopharmacology
About Journal of Psychopharmacology
Journal of Psychopharmacology is a peer-reviewed scholarly journal published by SAGE Publications Ltd (United Kingdom). It focuses on Q1. Publication coverage spans 1987-2026.
Key indicators: ISSN 1461-7285, 0269-8811; H-index 150.
Understanding This Journal's Metrics
Journal metrics help researchers assess fit, but they must be interpreted in context:
- H-index (150): Exceptionally high — 150 articles have each been cited at least 150 times. This indicates deep, sustained influence in the field.
Publishing in Journal of Psychopharmacology
An established venue in its field. The journal welcomes solid, well-executed research. Ensure your manuscript fits the stated scope and follows author guidelines carefully.
- Scope fit: Confirm your research aligns with Q1. Off-scope manuscripts are typically desk-rejected quickly.
- Author guidelines: Follow formatting, reference style, and article-type requirements exactly — non-compliant manuscripts may be returned without review.
- Submission: Submit via the official journal website.
Is This Journal Right for Your Paper?
- Audience match: Will the journal's readers cite and build on your findings?
- Timeline: Higher-tier journals mean longer review and higher rejection risk. Balance prestige against your schedule.
- Indexing: Confirm indexing in Web of Science, Scopus, and PubMed (if biomedical) meets your institutional requirements.
- Open access needs: Check funder mandates and whether the journal offers compliant OA options.
Frequently Asked Questions
What is the ISSN of Journal of Psychopharmacology?
1461-7285, 0269-8811.
Who publishes Journal of Psychopharmacology?
SAGE Publications Ltd.
What are Journal of Psychopharmacology's metrics?
H-index 150.
Where do I submit to Journal of Psychopharmacology?
Via the official website.
Is Journal of Psychopharmacology peer-reviewed?
Yes — it is a peer-reviewed scholarly journal indexed in major academic databases.
Source-backed journal facts
Topics in published research
Neurotransmitter Receptor Influence on Behavior; Schizophrenia research and treatment; Treatment of Major Depression; Psychedelics and Drug Studies; Neuroscience and Neuropharmacology Research; Forensic Toxicology and Drug Analysis.
OpenAlex classifies topics from published works. These topics are not the publisher’s official aims and scope.
Reported open-access list prices
4,400.00 USD; 3,226.00 GBP
APC list prices reported by OpenAlex, which obtains this information from DOAJ. Confirm current charges, taxes, waivers and eligibility with the publisher; this is not a fee quotation.
Source: OpenAlex source record. Retrieved 2026-10-03. Source record updated 2026-10-02. OpenAlex metrics are different from SCImago metrics and the Clarivate Journal Impact Factor.
Journal Metrics
Quartile, SJR and the listed SCImago H-index use the 2025 imported SCImago dataset. A quartile may vary by subject category. Values without a source or reporting year are unverified historical entries. Verify the current Journal Impact Factor with Clarivate or the publisher before using it.
Aims & Scope
The publisher’s official aims and scope have not yet been verified for this profile. Use the journal website to check subject fit and accepted article types before submitting.
Recent Research Articles
Latest publications matched automatically by ISSN.
Efficacy and safety of psilocybin-assisted therapy for alcohol use disorder: A systematic review and meta-analysis
Gianluca A. Florineth, Anna L. Boeker, Tobias Bracht, Alexander Wopfner et al.
2026-10-08 · DOI: 10.1177/02698811261490221Effects of Δ 9 -tetrahydrocannabinol on affiliative social behaviour: A systematic review of rodent studies
Mashal Ahmed, Christina F. Pereira, Laura M. Best, Raesham Mahmood et al.
2026-09-30 · DOI: 10.1177/02698811261478615Proper assessment of the response to a test drug needs a treatment-free control group in the experimental design
S. Clare Stanford, Simon T. Bate, Manuel Berdoy
2026-09-29 · DOI: 10.1177/02698811261488491Comment on “Urological symptoms following ketamine treatment for psychiatric disorders: A systematic review”
Nehal Taj Wali Khan, Hilal Khan, Bilal Ahmed, Syed Hassan Ali et al.
2026-09-29 · DOI: 10.1177/02698811261490197Ketamine-enhanced psychotherapy for smoking cessation: A pilot study of feasibility, safety, and clinical outcomes
Jennifer Jones, Joseph Redding, Emily Amador
2026-09-25 · DOI: 10.1177/02698811261488486Early intervention with clozapine: Is there a neurobiological critical period for treatment-resistant schizophrenia?
Rajeev Krishnadas, I Lam Leong, Joanna Fraczek, Emilio Fernandez-Egea et al.
2026-09-25 · DOI: 10.1177/02698811261488465Chronopharmacology and implications for the safety and efficacy of anticonvulsants, antipsychotics, and antidepressants: A systematic review
Victoria Yue Tan, Sabrina Wong, Gia Han Le, Angela T. H. Kwan et al.
2026-09-25 · DOI: 10.1177/02698811261488466N,N-Dimethyltryptamine and harmine formulation alters transient EEG topography sequences near the peak of the psychedelic state
Maria Niedernhuber, Dila Suay, Bigna Lenggenhager, Michael Müller et al.
2026-09-22 · DOI: 10.1177/02698811261481062Validating and creating a short-form of the persisting effects questionnaire: A measure of positive and negative outcomes from psychedelic experiences
Rebecca Ehrenkranz, Nathan D. Sepeda, Sean P. Goldy, Brandon M. Weiss et al.
2026-09-18 · DOI: 10.1177/02698811261473405Defining the intervention before estimating efficacy in DMT-assisted therapy
Kenjiro Shiraishi
2026-09-17 · DOI: 10.1177/02698811261488484Adjunctive GLP-1 receptor agonists for cardiometabolic risk in antipsychotic-treated patients: A GRADE-assessed meta-analysis of randomized trials
Elsayed S. Moubarak, Mohamed S. Elgendy, Omar Elkoumi, Ahmed A. Ibrahim et al.
2026-09-16 · DOI: 10.1177/02698811261478625Psychedelic therapy without durable effects: A review and re-evaluation of controlled studies between 1965 and 1977
Torsten Passie, Michiel van Elk
2026-09-07 · DOI: 10.1177/02698811261478606The effect of ketamine on mitochondrial bioenergetics, viability, and function: A systematic review
Sabrina Wong, Gia Han Le, Simryn Selby, Stavroula Bargiota et al.
2026-09-07 · DOI: 10.1177/02698811261481085Psilocybin-induced changes in electroencephalography link acute and long-term effects
Marek Nikolič, Tom Froese, Pedro A. M. Mediano, Vlastimil Koudelka et al.
2026-09-04 · DOI: 10.1177/02698811261473445Safety, pharmacokinetics, and pharmacodynamics of intravenously administered deuterated N,N -dimethyltryptamine (CYB004) in healthy volunteers
Katelijne V. van der Heijden, Gabriel E. Jacobs, Ellen H. James, Pradeep J. Nathan et al.
2026-09-03 · DOI: 10.1177/02698811261478616Safety, tolerability and pharmacokinetics of an NMDA receptor subunit 2B-selective negative allosteric modulator, BI 1569912: Results of three partially randomised, placebo-controlled phase I trials
Andreas Hünnemeyer, Yoichiro Ogama, Franco De Crescenzo, Rainer-Georg Goeldner et al.
2026-09-02 · DOI: 10.1177/02698811261481073Reinstatement of escitalopram and clonidine administration reverses the cessation-induced enhanced activation of rat norepinephrine and serotonin neuronal firing activity
Mostafa El Mansari, Naomichi Okamoto, Pierre Blier
2026-09-01 · DOI: 10.1177/02698811261478602Pharmacokinetics, pharmacodynamics and safety of N,N -dimethyltryptamine administered intravenously in healthy smoking and non-smoking volunteers
Katelijne V. van der Heijden, Soma Makai- Bölöni, Amir Inamdar, Marije E. Otto et al.
2026-08-31 · DOI: 10.1177/02698811261473451A novel approach for evaluating and comparing multiple antipsychotic polypharmacy in adults across specialist intellectual disability services in England and Wales: A retrospective feasibility cohort study
Samuel J. Tromans, Helen Neilens, Crispin Musicha, Victoria Allgar et al.
2026-08-31 · DOI: 10.1177/02698811261478609Differential effects of psilocybin derivatives on fentanyl-induced conditioned place preference in male and female mice
Tiffini N. Lovell, Peter B. James, Skylar L. Hodgins, Samuel Johnson Noya et al.
2026-08-30 · DOI: 10.1177/02698811261478613Reviews
Community Reviews
Version History
October 9, 2026 at 7:06 pm
September 25, 2026